Physician profile
Maysoon Salem
NPI 1982363545
$1,453.75
in general payments reported to CMS, 2019-2025
12 companies · $479 in 2025
The $479 reported for 2025 was more than what 76% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $123 · 2023: $564 · 2024: $288 · 2025: $479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,102 · Travel and Lodging: $229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,101.92 |
| Travel and Lodging | $229.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $249.21 | 2023-2025 | Dailies Total1 Multifocal, Dailies Aqua Comfort Plus, Air Optix |
| Oyster Point Pharma, INC. | $244.88 | 2022-2024 | Tyrvaya, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $207.53 | 2022-2025 | Cequa |
| Glaukos Corporation | $180.86 | 2025 | |
| Bausch & Lomb Americas INC. | $166.01 | 2022-2025 | Miebo, Infuse, Vyzulta |
| Harrow Eye, LLC | $148.83 | 2024-2025 | Vevye |
| Coopervision INC. | $82.57 | 2024-2025 | Clariti Contact Lens, Myday Contact Lens |
| Dompe US, INC. | $57.25 | 2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $38.61 | 2024 | Xdemvy |
| Johnson & Johnson Vision Care, INC. | $33.72 | 2024 | |
| Novartis Pharmaceuticals Corporation | $25.30 | 2023 | |
| Sight Sciences, INC. | $18.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maysoon Salem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.